{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["69(9)"],"submitter":["Ji S"],"pubmed_abstract":["Introduction
Alzheimer's disease (AD) is a major public health concern worldwide, but there are still no drugs available that treat it effectively. Previous studies have shown that phenylethanoid glycosides have pharmacological effects, which include anti-AD properties, but the underlying mechanisms by which they ameliorate AD symptoms remain unknown.Methods
In this study, we used an APP/PS1 AD mouse model to explore the function and mechanisms underlying savatiside A (SA) and torenoside B (TB) in the treatment of AD. SA or TB (100 mg·kg-1·d-1) was orally administered to 7-month-old APP/PS1 mice for 4 weeks. Cognitive and memory functions were measured using behavioral experiments (including the Morris water maze test and the Y-maze spontaneous alternation test). Molecular "],"journal":["Gerontology"],"pagination":["1065-1075"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10568609"],"repository":["biostudies-literature"],"pubmed_title":["Novel Phenylethanoid Glycosides Improve Hippocampal Synaptic Plasticity via the Cyclic Adenosine Monophosphate-CREB-Brain-Derived Neurotrophic Growth Factor Pathway in APP/PS1 Transgenic Mice."],"pmcid":["PMC10568609"],"pubmed_authors":["Jiang Y","Ji S","Yu L","Ma X","Guo D","Huang L","Zhu R","Wu Y"],"additional_accession":[]},"is_claimable":false,"name":"Novel Phenylethanoid Glycosides Improve Hippocampal Synaptic Plasticity via the Cyclic Adenosine Monophosphate-CREB-Brain-Derived Neurotrophic Growth Factor Pathway in APP/PS1 Transgenic Mice.","description":"Introduction
Alzheimer's disease (AD) is a major public health concern worldwide, but there are still no drugs available that treat it effectively. Previous studies have shown that phenylethanoid glycosides have pharmacological effects, which include anti-AD properties, but the underlying mechanisms by which they ameliorate AD symptoms remain unknown.Methods
In this study, we used an APP/PS1 AD mouse model to explore the function and mechanisms underlying savatiside A (SA) and torenoside B (TB) in the treatment of AD. SA or TB (100 mg·kg-1·d-1) was orally administered to 7-month-old APP/PS1 mice for 4 weeks. Cognitive and memory functions were measured using behavioral experiments (including the Morris water maze test and the Y-maze spontaneous alternation test). Molecular ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2025-04-05T11:54:10.909Z","creation":"2025-04-05T11:54:10.909Z"},"accession":"S-EPMC10568609","cross_references":{"pubmed":["37285833"],"doi":["10.1159/000531194"]}}